✦ LIBER ✦

Long-term safety and efficacy of continuous intrathecal baclofen

✍ Scribed by William M Campbell; Anne Ferrel; John F McLaughlin; Gerald A Grant; John D Loeser; Catherine Graubert; Kristie Bjornson

Book ID: 111129594
Publisher: John Wiley and Sons
Year: 2007
Tongue: English
Weight: 64 KB
Volume: 44
Category: Article
ISSN: 0012-1622
DOI: 10.1111/j.1469-8749.2002.tb00267.x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Poster 297 Long-Term Safety, Efficacy, a

Poster 297 Long-Term Safety, Efficacy, and Satisfaction of Intrathecal Baclofen Pumps

✍ Mathur, Sunjay; Dudas-Sheehan, Diane; Duraski, Sylvia A.; Marciniak, Christina M 📂 Article 📅 2012 🏛 Wiley (John Wiley & Sons) 🌐 English ⚖ 51 KB

Long-term Outcomes of Intrathecal Baclof

Long-term Outcomes of Intrathecal Baclofen for Spasticity

✍ McCormick, Zack; Chu, Samuel K.; Mathur, Sunjay; Marciniak, Christina M. 📂 Article 📅 2013 🏛 Wiley (John Wiley & Sons) 🌐 English ⚖ 44 KB

364 INTRATHECAL BACLOFEN FOR INTRACTABLE

364 INTRATHECAL BACLOFEN FOR INTRACTABLE NEUROPATHIC PAIN – PREDICTIVE STUDY OF EFFICACY AND LONG TERM RESULTS

✍ A. Margot-Duclot; B. Silhouette; J.-B. Thiebaut 📂 Article 📅 2010 🏛 Wiley (John Wiley & Sons) 🌐 English ⚖ 43 KB

393 LONG TERM FOLLOW-UP AFTER CONTINUOUS

393 LONG TERM FOLLOW-UP AFTER CONTINUOUS INTRATHECAL BACLOFEN THERAPY FOR SEVERE SPASTICITY

✍ E. Anastasiou; A. Tzortzopoulou; A. Alexandropoulou; K. Rizos; A. Karakosta; A. 📂 Article 📅 2010 🏛 Wiley (John Wiley & Sons) 🌐 English ⚖ 43 KB

Continuous infusion of intrathecal baclo

Continuous infusion of intrathecal baclofen: long-term effects on spasticity in spinal cord injury

✍ Loubser, P G ;Narayan, R K ;Sandin, K J ;Donovan, W H ;Russell, K D 📂 Article 📅 1991 🏛 Nature Publishing Group 🌐 English ⚖ 520 KB

Long-term efficacy and safety of deferas

Long-term efficacy and safety of deferasirox

✍ Maria Domenica Cappellini 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 117 KB

Deferasirox is an oral iron chelator, with a long half-life, that can be given once daily, because it provides a 24-hour chelation. Several phase II trials and a pivotal phase III trial have established that, in transfusion-dependent patients with beta-thalassaemia major, deferasirox has a similar e